Company Overview of Enumeral Biomedical Holdings, Inc.
Key Executives for Enumeral Biomedical Holdings, Inc.
|Kevin G. Sarney CPA||5 Relationships||Interim CEO, Interim President, VP of Finance, Chief Accounting Officer, Treasurer & Director||52|
|Barry C. Buckland Ph.D.||48 Relationships||Co-Founder & Chairman of Scientific Advisory Board||69|
|Matthew A. Ebert||No Relationships||General Counsel and Secretary||--|
Enumeral Biomedical Holdings, Inc. Board Members*
|Name||Board Relationships||Primary Company||Age|
|Wael Fayad||5 Relationships||Enumeral Biomedical Holdings, Inc.||50|
|Kevin G. Sarney CPA||5 Relationships||Enumeral Biomedical Holdings, Inc.||52|
|Barry C. Buckland Ph.D.||48 Relationships||Enumeral Biomedical Holdings, Inc.||69|
|Robert L. Van Nostrand BS||37 Relationships||Yield10 Bioscience, Inc.||60|
|Giulio Draetta M.D., Ph.D.||101 Relationships||Karyopharm Therapeutics Inc.||--|
Enumeral Biomedical Holdings, Inc. Executive Committees*
|Committee Name||Chairperson||Board Relationships||Members|
|Nominating Committee Ph.D.||Barry C. Buckland||48 Relationships||2 Executives|
|Corporate Governance Committee Ph.D.||Barry C. Buckland||48 Relationships||2 Executives|
|Advisory Board Ph.D.||Barry C. Buckland||48 Relationships||3 Executives|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
CEO COMPENSATION IN THIS INDUSTRY
|Total Short Term Compensation|
|Total Value of Options||$310.0K|
INDUSTRY EXECUTIVE CHANGES
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.